News & Events
BD in India Launches the BD Venflon™ Pro Safety IV Catheter
|
Safeguards healthcare workers against needlestick injuries and blood exposure New Delhi, India (May 3, 2007) – BD Medical, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, today launched the BD Venflon™ Pro Safety IV Catheter with safety features against needlestick injury. This product is unique in its category for offering not only robust protection against needlestick injuries but also minimizing the risk due to blood exposure. Needlestick injuries can lead to the transmission of fatal bloodborne infections including hepatitis B virus (HBV), hepatitis C virus (HCV) and the human immunodeficiency virus (HIV). Each year, sharps injuries are responsible for 65,600 new HBV infections, 16,400 new HCV infections and 1,000 new HIV infections.* According to a study conducted at the Hinduja hospital in Mumbai, most needlestick injuries occur during intravenous line insertion, followed by blood collection and then surgical blade injury and recapping needles.** The BD Venflon Pro Safety Catheter has an advanced needle shield design to safeguard healthcare workers from needlestick injuries. Once activated, the needle tip is encapsulated inside the smooth-edged plastic shield, thereby reducing the risk of healthcare workers injuring themselves with the sharp needle tip. In fact, in a recent study conducted in Europe, over 86% of the clinicians surveyed gave BD Venflon Pro Safety Catheter a more than adequate rating for protection against needlestick injuries.*** A study conducted by the market research agency PQR in India in December 2006 revealed that many clinicians felt that existing safety IV catheters in the market did not provide adequate protection against blood exposure. BD Venflon™ Pro Safety IV Catheter has been designed to reduce blood splatter and blood exposure. In addition, the BD Vialon™ biomaterial used in the catheter was shown in a study to reduce the risk of all phlebitis cases by nearly 30% and deliver longer in-dwelling time. **** The biomaterial softens once inside the vein conforming to the shape of the vein. About BD BD started operations in India in 1996, a century after its genesis in New Jersey, USA, and initiated a new era in patient safety in India with its world-class products. It operates in India through a wholly-owned subsidiary, Becton Dickinson India Pvt. Ltd. BD in India has a world-class, state-of-the-art manufacturing facility at Bawal near Rewari in Haryana, with an initial outlay of Rs. 110 crores. This facility is amongst the largest syringe and medical device manufacturing plants in Asia and produces products recognized around the world, including disposable needles, syringes and catheters. The manufacturing techniques are of international standards and the factory has been recognized by the Haryana State Industrial Corporation.
*** Data on file, from a recent Clinical study in Europe **** Risk Factors for Infusion-related Phlebitis with Small Peripheral Venous Catheters" Annals of Internal Medicine, 1991;114:845-854,Dennis G. Maki, M.D, and Marilyn Ringer, BSN, MS Dennis Maki MD and Marilyn Ringer
|